Table 1.
Guidelines | Stroke risk assessment |
Bleeding risk assessment | ||
---|---|---|---|---|
Scoring scheme suggested for stroke risk assessment | Definitions of the stroke risk factor component | Other important statements | Scoring scheme suggested for bleeding risk assessment | |
2017 APHRS | CHA2DS2-VASc | Similar to the original definitions | — | HAS-BLED score |
2018 ACCP | CHA2DS2-VASc | C: Recent decompensated HF, irrespective of the ejection fraction or the presence of moderate-severe LV systolic impairment on cardiac imaging, whether symptomatic or asymptomatic | — | HAS-BLED score |
2019 ACC/AHA/HRS | CHA2DS2-VASc | Similar to the original definitions | — | No specific bleeding score was recommended |
2020 ESC | CHA2DS2-VASc |
C: Clinical HF, or objective evidence of moderate to severe LV dysfunction, or HCM V: Angiographically significant CAD, previous myocardial infarction, PAD, or aortic plaque |
H: Uncontrolled BP—the optimal BP target associated with the lowest risk of ischaemic stroke, death, and other cardiovascular outcomes is 120–129/<80 mmHg Age: Age-related risk is a continuum, but for reasons of simplicity and practicality, 1 point is given for age 65–74 years, and 2 points for age ≥75 years Recent data from Asia suggest that the risk of stroke may rise from age 50–55 years upwards and that a modified CHA2DS2-VASc score may be used in Asian patients Sc: Female sex is a stroke risk modifier rather than a risk factor |
HAS-BLED score |
ACC/AHA/HRS, American College of Cardiology/American Heart Association/Heart Rhythm Society; ACCP, American College of Chest Physicians; APHRS, Asia Pacific Heart Rhythm Society; BP, blood pressure; CAD, coronary artery disease; ESC, European Society of Cardiology; HF, heart failure; LV, left ventricle; PAD, peripheral arterial disease.